Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

April 10, 2026 DMDWarrioR

The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2026.

Read More Editorials

Next Generation Exon Skipping Therapies Developed for the Treatment of DMD

January 16, 2025 DMDWarrioR

Next generation exon skipping therapies for Duchenne Muscular Dystrophy (DMD) represent a promising area of research aimed at addressing the underlying genetic mutations that cause the disease.

Read More Research

What is Duchenne Muscular Dystrophy?

February 27, 2026 DMDWarrioR

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that affects thousands of families worldwide. It primarily impacts boys, causing muscle degeneration and weakness over...

Read More DMD

We Call on Health Ministries and Pharmaceutical Manufacturers to Take Action on DMD

February 16, 2025 DMDWarrioR

We call on all health ministries around the world and manufacturers of DMD treatments approved by the FDA and EMA to take action.

Read More Editorials

Genetic Causes of Duchenne Muscular Dystrophy

October 4, 2024 DMDWarrioR

Duchenne muscular dystrophy (DMD) is rooted in the intricate world of genetics, specifically emanating from changes in a single gene known as the Dystrophin...

Read More DMD

Does My Child Have Duchenne Muscular Dystrophy (DMD)?

October 4, 2024 DMDWarrioR

When parents ponder the question, “Does My Child Have Duchenne Muscular Dystrophy (DMD)?” they often find themselves grappling with a whirlwind of emotions as...

Read More DMD

With a mission to cure Duchenne muscular dystrophy

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable. Together, we will cure Duchenne muscular dystrophy!

DMD Warriors can overcome any challenge.

What is our purpose?

One in every 5,000 children in the world is born with DMD, and many families only realize their child has the disease when they are 3-4 years old. FDA-approved treatments for DMD are too expensive for families to afford. Our goal is to reduce treatment costs and have the costs covered by the government.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness on Social Media

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

Duchenne News & Articles

DYNE-251 Phase 3 FORZETTO Clinical Trial of Z-Rostudirsen Officially Begins for DMD

Dyne Therapeutics has announced the start of the Dyne Therapeutics Phase 3 FORZETTO Trial (NCT07608432) of Z-Rostudirsen for DMD, marking another major step forward...

What Is a Spirometry Test in Duchenne Muscular Dystrophy (DMD) and Why Is It Performed?

A spirometry test in Duchenne muscular dystrophy is a simple, non-invasive breathing test used to evaluate how well the lungs and respiratory muscles are...

Age-Based Assistive Devices for Duchenne Muscular Dystrophy: Complete Guide by Stage

Age-based assistive devices for Duchenne muscular dystrophy (DMD) plays a critical role in preserving mobility, independence, respiratory health, posture, communication, and quality of life...

Del-Zota SAFARI44 Phase 3 Trial: A New Exon 44 Skipping Study for Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) research continues to move forward with the launch of the Del-Zota SAFARI44 Phase 3 clinical trial evaluating AOC 1044, also...

RGX-202 Duchenne Gene Therapy Shows NSAA Improvement and Microdystrophin Expression — But Important Biomarker Data Missing

REGENXBIO recently announced positive topline results from the Phase 3 portion of the AFFINITY DUCHENNE trial evaluating RGX-202, an investigational gene therapy for Duchenne...